Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "With FDA Releasing Final Guidance for Mobile Health Apps, Innovators Have Clarity on Regulatory Policy."
Following is an excerpt:
The FDA this week issued its final guidance on mobile medical apps and noted that it hopes this guidance will both protect patients and "encourage innovation." ...
The final guidance from the FDA represents "a huge step forward" and also states very clearly the agency's intentions moving forward, according to Bradley Merrill Thompson, a lawyer with Epstein, Becker & Green. "They took the ambiguous area and made it much more spelled out," Thompson told The Wall Street Journal. "The usual situation with FDA is a dozen or so institutions file comments, and FDA changes a few words before finalizing the guidance document. In this case, FDA made massive changes."
Thompson has represented medical-device companies in the past, the newspaper noted.
